Last reviewed · How we verify
Dexmedetomidine IV — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Dexmedetomidine IV (Dexmedetomidine IV) — Samsung Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dexmedetomidine IV TARGET | Dexmedetomidine IV | Samsung Medical Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dexmedetomidine IV CI watch — RSS
- Dexmedetomidine IV CI watch — Atom
- Dexmedetomidine IV CI watch — JSON
- Dexmedetomidine IV alone — RSS
Cite this brief
Drug Landscape (2026). Dexmedetomidine IV — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-iv. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing